[go: up one dir, main page]

MX2018012537A - Terapia de genes para tratar hemofilia a. - Google Patents

Terapia de genes para tratar hemofilia a.

Info

Publication number
MX2018012537A
MX2018012537A MX2018012537A MX2018012537A MX2018012537A MX 2018012537 A MX2018012537 A MX 2018012537A MX 2018012537 A MX2018012537 A MX 2018012537A MX 2018012537 A MX2018012537 A MX 2018012537A MX 2018012537 A MX2018012537 A MX 2018012537A
Authority
MX
Mexico
Prior art keywords
treating hemophilia
gene therapy
compositions
hemophilia
treating
Prior art date
Application number
MX2018012537A
Other languages
English (en)
Inventor
Wang Lili
M Wilson James
Agnes SIDRANE Jenny
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2018012537A publication Critical patent/MX2018012537A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan composiciones y regimenes utiles en el tratamiento de hemofilia A; las composiciones incluyen un virus recombinante adeno-asociado (rAAV) con un mejorador y promotor de transtiretina que conducen a la expresion de un Factor VIII humano.
MX2018012537A 2016-04-15 2017-04-13 Terapia de genes para tratar hemofilia a. MX2018012537A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662323336P 2016-04-15 2016-04-15
US201662331807P 2016-05-04 2016-05-04
US201662428866P 2016-12-01 2016-12-01
PCT/US2017/027396 WO2017180857A1 (en) 2016-04-15 2017-04-13 Gene therapy for treating hemophilia a

Publications (1)

Publication Number Publication Date
MX2018012537A true MX2018012537A (es) 2019-02-25

Family

ID=59253992

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012537A MX2018012537A (es) 2016-04-15 2017-04-13 Terapia de genes para tratar hemofilia a.

Country Status (17)

Country Link
US (3) US11779656B2 (es)
EP (1) EP3452102B9 (es)
JP (2) JP7347933B2 (es)
KR (1) KR102450833B1 (es)
CN (1) CN109562191A (es)
AU (1) AU2017248659B2 (es)
BR (1) BR112018071200A2 (es)
CA (1) CA3019425A1 (es)
IL (1) IL262215B2 (es)
MX (1) MX2018012537A (es)
PE (2) PE20250736A1 (es)
RU (1) RU2762257C2 (es)
SA (1) SA518400233B1 (es)
SG (2) SG11201808422QA (es)
TW (1) TWI791433B (es)
WO (1) WO2017180857A1 (es)
ZA (1) ZA201806477B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2985035T3 (es) 2008-09-15 2024-11-04 Uniqure Biopharma B V Mutante de polipéptido de factor IX, sus usos y su procedimiento de producción
KR102877920B1 (ko) 2015-11-16 2025-10-30 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 티틴-기반 근증 및 다른 티틴성병증의 치료를 위한 물질 및 방법
US11191847B2 (en) 2016-04-15 2021-12-07 The Trustees Of The University Of Pennsylvania Gene therapy for treating hemophilia B
PE20250736A1 (es) * 2016-04-15 2025-03-10 Univ Pennsylvania Terapia genica para tratar la hemofilia a
AU2019216257B2 (en) 2018-01-31 2025-11-20 Research Institute At Nationwide Children's Hospital Gene therapy for limb-girdle muscular dystrophy type 2C
WO2020006458A1 (en) 2018-06-29 2020-01-02 Research Institute At Nationwide Children's Hospital Recombinant adeno-associated virus products and methods for treating limb girdle muscular dystrophy 2a
JOP20210054A1 (ar) * 2018-09-21 2020-03-21 Nightstarx Ltd تركيبات وطرق لعلاج التهاب الشبكية الصباغي
US20210348135A1 (en) * 2018-10-12 2021-11-11 Genzyme Corporation Generation of improved human pah for treatment of severe pku by liver-directed gene replacement therapy
EP3867412A1 (en) * 2018-10-15 2021-08-25 REGENXBIO Inc. Method for measuring the infectivity of replication defective viral vectors and viruses
BR112021007229A2 (pt) 2018-10-16 2021-08-10 Blueallele, Llc métodos para inserção dirigida de dna em genes
GB201818816D0 (en) * 2018-11-19 2019-01-02 Synpromics Ltd Regulatory nucleic acid sequences
TWI851647B (zh) * 2019-01-16 2024-08-11 日商武田藥品工業股份有限公司 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體
US12377170B2 (en) * 2019-02-26 2025-08-05 Research Institute At Nationwide Children's Hospital Adeno-associated virus vector delivery of β-sarcoglycan and the treatment of muscular dystrophy
MX2021011039A (es) * 2019-03-13 2021-12-15 Generation Bio Co Vectores de adn no virales y usos de estos para expresar agentes terapéuticos con fviii.
EP4017871B1 (en) 2019-08-21 2024-01-17 Research Institute at Nationwide Children's Hospital Adeno-associated virus vector delivery of alpha-sarcoglycan and the treatment of muscular dystrophy
JP2023501262A (ja) * 2019-11-01 2023-01-18 フリーライン セラピューティクス リミテッド 転写調節エレメント
CN111218446B (zh) * 2019-12-25 2023-03-28 劲帆生物医药科技（武汉）有限公司 一种肝脏特异性启动子及其应用
EP4090382A2 (en) * 2020-01-16 2022-11-23 Takeda Pharmaceutical Company Limited Adeno associated virus based gene therapy for phenylketonuria
KR20230010670A (ko) 2020-05-12 2023-01-19 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 이식유전자 발현의 drg-특이적 감소를 위한 조성물
WO2022165245A1 (en) * 2021-01-29 2022-08-04 The Trustees Of The University Of Pennsylvania Compositions and method of use of mutant ace2 decoy variants
JP2024506860A (ja) * 2021-02-01 2024-02-15 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア ニーマンピック病ａ型を治療するための組成物及び方法
CA3209779A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses
JP2023059858A (ja) 2021-10-15 2023-04-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用
US20240335564A1 (en) * 2021-11-02 2024-10-10 Gritgen Therapeutics Limited Isolated nucleic acid molecule and use thereof
US20250295807A1 (en) 2021-11-15 2025-09-25 The Trustees Of The University Of Pennsylvania Compositions for drg-specific reduction of transgene expression
WO2023205300A2 (en) * 2022-04-20 2023-10-26 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus using codon optimized nucleic acid encoding factor viii
US20250352626A1 (en) * 2022-06-10 2025-11-20 University Of Florida Research Foundation, Incorporated Immune tolerance induction to viral capsids

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5439824A (en) 1993-05-06 1995-08-08 The United States Of America Increased expression of α-1-antitrypsin in expression vectors through the inclusion of intron II
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
WO1998000541A2 (en) * 1996-07-03 1998-01-08 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
AU735763B2 (en) 1997-12-05 2001-07-12 Immune Response Corporation, The Novel vectors and genes exhibiting increased expression
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
US6797505B2 (en) 1998-05-27 2004-09-28 Cell Genesys, Inc. Recombinant AAV vectors for gene therapy of hemophilia A
US6200560B1 (en) * 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
US6221349B1 (en) * 1998-10-20 2001-04-24 Avigen, Inc. Adeno-associated vectors for expression of factor VIII by target cells
EP1038959A1 (en) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Factor VIII without B-domain, comprising one or more insertions of a truncated intron I of factor IX
US6610906B1 (en) 1999-06-09 2003-08-26 The Regents Of The University Of Michigan Nucleotide sequences for gene regulation and methods of use thereof
EP1224312A1 (en) 1999-10-12 2002-07-24 The University of North Carolina at Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
ATE360082T1 (de) 1999-11-16 2007-05-15 Genzyme Corp Vektoren und transgene mit regulatorischen elementen zur genverabreichung in leber
DE60115613T2 (de) 2000-03-22 2006-08-24 Octagene Gmbh Herstellung von rekombinanten muteine des blutgerinnungsfaktors viii in humanen zellinien
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
US7351813B2 (en) 2000-06-20 2008-04-01 The Board Of Trustees Of The Leland Stanford Junior University Liver-specific gene expression cassettes, and methods of use
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030147853A1 (en) 2001-03-14 2003-08-07 Mcclelland Alan Recombinant adeno-associated virus-mediated gene transfer via retroductal infusion of virions
US8021875B2 (en) 2001-08-27 2011-09-20 Roche Madison Inc. Methods for expression of transgenes
JP4634036B2 (ja) 2001-10-05 2011-02-16 エクスプレッション セラピューティクス， エルエルシー 高レベルエキスプレッサー第ｖｉｉｉ因子ポリペプチドをコードする核酸配列およびアミノ酸配列および使用方法
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
PT2359869T (pt) 2001-12-17 2019-04-16 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
US20080050357A1 (en) 2003-08-01 2008-02-28 Claes Gustafsson Systems and Methods for Antibody Engineering
US8005620B2 (en) 2003-08-01 2011-08-23 Dna Twopointo Inc. Systems and methods for biopolymer engineering
EP2292780B1 (en) 2003-09-30 2017-08-23 The Trustees Of The University Of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
ATE417066T1 (de) 2003-10-16 2008-12-15 Claude Negrier Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
DE602004026474D1 (de) 2003-12-03 2010-05-20 Univ Rochester Rekombinanter faktor viii mit erhöhter spezifischer aktivität
ES2381796T3 (es) 2004-09-22 2012-05-31 St. Jude Children's Research Hospital Expresión mejorada de Factor IX en vectores de terapia génica
US8008468B2 (en) 2005-02-16 2011-08-30 Benitec, Inc. RNAi expression constructs with liver-specific enhancer/promoter
WO2006102072A2 (en) 2005-03-23 2006-09-28 The Trustees Of The University Of Pennsylvania Use of a pa131 polypeptide in treatment of atherosclerosis
KR20080007226A (ko) 2005-04-14 2008-01-17 체에스엘 베링 게엠베하 증가된 안정성을 가진 변형된 응고 인자 ⅷ 및 이의 유도체
WO2007016331A2 (en) 2005-07-29 2007-02-08 Children's Hospital Medical Center Classification and diagnosis of the molecular basis of cholestasis
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007078599A2 (en) 2005-12-16 2007-07-12 The Board Of Trustees Of The Leland Stanford Junior University Functional arrays for high throughput characterization of gene expression regulatory elements
EP1979485A2 (en) 2006-01-31 2008-10-15 The Board Of Trustees Of The Leland Stanford Junior University Self-complementary parvoviral vectors, and methods for making and using the same
US8129510B2 (en) * 2006-03-30 2012-03-06 The Board Of Trustees Of The Leland Stanford Junior University Minigene expression cassette
EP2037892B1 (en) 2006-06-19 2015-03-18 Asklepios Biopharmaceutical, Inc. Modified factor viii and factor ix genes and vectors for gene therapy
WO2008073303A2 (en) 2006-12-07 2008-06-19 Switchgear Genomics Transcriptional regulatory elements of biological pathways, tools, and methods
JP5448839B2 (ja) 2006-12-22 2014-03-19 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー インビボで長い半減期を有する修飾された凝固因子
CA2676090A1 (en) 2007-02-06 2008-10-02 Genizon Biosciences Inc. Genemap of the human genes associated with adhd
KR101235560B1 (ko) 2008-02-14 2013-02-25 재단법인 목암생명공학연구소 유전자 치료용 코딩 서열의 발현에 적합한 발현 벡터
KR100981092B1 (ko) 2008-02-29 2010-09-08 고려대학교 산학협력단 제8 혈액응고 인자와 폰 빌리 블란트 인자 변이체의 재조합발현 벡터 시스템
EP2271763A2 (en) 2008-04-03 2011-01-12 Yeda Research And Development Company Ltd. Methods of expressing a polypeptide in the brain and nucleic acid constructs capable of same
WO2009130208A1 (en) 2008-04-22 2009-10-29 Vib Vzw Liver-specific nucleic acid regulatory elements and methods and use thereof
US20110306512A1 (en) 2008-06-25 2011-12-15 Dxterity Diagnostics Gene Expression Profiling for Identification, Monitoring, and Treatment of Osteoarthritis
KR101034811B1 (ko) 2008-08-25 2011-05-16 단국대학교 산학협력단 조직 특이적 프로모터와 암 특이 유전자를 타겟팅하는트랜스-스플라이싱 라이보자임을 포함하는 재조합아데노바이러스 및 이의 용도
AU2010227419A1 (en) 2009-03-27 2011-10-20 Proyecto De Biomedicina Cima, S.L. Methods and compositions for the treatment of cirrhosis and liver fibrosis
CN101935674A (zh) * 2009-06-30 2011-01-05 中国医学科学院血液学研究所 一种用于血友病b基因治疗的腺病毒载体及其用途
GB0911870D0 (en) 2009-07-08 2009-08-19 Ucl Business Plc Optimised coding sequence and promoter
WO2011109380A1 (en) 2010-03-01 2011-09-09 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the hcv genome
US9315825B2 (en) * 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
SG183929A1 (en) 2010-03-29 2012-10-30 Univ Pennsylvania Pharmacologically induced transgene ablation system
EP2394667A1 (en) 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vectors and sequences for the treatment of diseases
HRP20140392T1 (hr) * 2010-09-02 2014-06-06 Molmed Spa Stabilna proizvodnja lentiviralnih vektora
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
DK2911687T3 (da) 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
EP3513802B1 (en) * 2012-10-26 2023-11-29 Vrije Universiteit Brussel Vector for liver-directed gene therapy of hemophilia and methods and use thereof
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
AU2014318890B2 (en) * 2013-09-12 2019-03-07 Biomarin Pharmaceutical Inc. Adeno-associated virus Factor VIII vectors
EP3253786A4 (en) * 2015-02-06 2018-10-17 The University of North Carolina at Chapel Hill Optimized human clotting factor viii gene expression cassettes and their use
WO2016176191A1 (en) * 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Dual aav vector system for crispr/cas9 mediated correction of human disease
US10189888B2 (en) * 2015-11-13 2019-01-29 Baxalta Incorporated Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
ES2918998T3 (es) 2015-12-11 2022-07-21 Univ Pennsylvania Método de purificación escalable para AAVrh10
PE20250736A1 (es) * 2016-04-15 2025-03-10 Univ Pennsylvania Terapia genica para tratar la hemofilia a

Also Published As

Publication number Publication date
IL262215B1 (en) 2023-03-01
AU2017248659A1 (en) 2018-10-18
ZA201806477B (en) 2024-09-25
US10888628B2 (en) 2021-01-12
CA3019425A1 (en) 2017-10-19
WO2017180857A1 (en) 2017-10-19
US20200085975A1 (en) 2020-03-19
CN109562191A (zh) 2019-04-02
JP2019513794A (ja) 2019-05-30
JP7347933B2 (ja) 2023-09-20
KR102450833B1 (ko) 2022-10-05
IL262215B2 (en) 2023-07-01
IL262215A (en) 2018-11-29
EP3452102B9 (en) 2024-09-04
US11779656B2 (en) 2023-10-10
KR20190032274A (ko) 2019-03-27
RU2018136611A (ru) 2020-05-15
EP3452102B1 (en) 2024-06-12
JP2022062121A (ja) 2022-04-19
RU2018136611A3 (es) 2020-08-11
PE20181922A1 (es) 2018-12-11
AU2017248659B2 (en) 2022-08-11
SG10202009849WA (en) 2020-11-27
TW201741458A (zh) 2017-12-01
EP3452102A1 (en) 2019-03-13
BR112018071200A2 (pt) 2019-04-09
US20190343966A1 (en) 2019-11-14
PE20250736A1 (es) 2025-03-10
US20240000974A1 (en) 2024-01-04
RU2762257C2 (ru) 2021-12-17
SA518400233B1 (ar) 2022-08-23
TWI791433B (zh) 2023-02-11
SG11201808422QA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
ZA201806477B (en) Gene therapy for treating hemophilia a
MX2019007876A (es) Terapia genetica para tratar fenilcetonuria.
EP4361277A3 (en) Gene therapy for treating wilson's disease
WO2018144709A3 (en) Gene therapy for treating citrullenemia
IL270567B (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
PH12018500594A1 (en) Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same
BR112018071167A2 (pt) entrega de beta-sarcoglicano e microrna-29 por vírus adenoassociado e tratamento de distrofia muscular
SA520412637B1 (ar) B7 الفيروس الغدي الحال للورم المشفِّر لبروتين
CR20160480A (es) Terapia genetica para la retinitis pigmentaria
EP4491733A3 (en) Modulation of aav vector transgene expression
MX2021012014A (es) Vectores del factor viii del virus adeno-asociado.
EA201891137A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
MX2018006840A (es) Focalizacion de peptidos para dirigir virus adenoasociados.
EA201592014A1 (ru) Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса
EP4403229A3 (en) Expression of pten-long with oncolytic viruses
NZ726316A (en) Adenoassociated virus vectors for the treatment of lysosomal storage disorders
UY36106A (es) Vectores aav para terapia génica retiniana y del snc.
EA201890543A1 (ru) Способы и материалы для генной терапии galgt2
CY1123312T1 (el) Aav-βασιζομενη γονιδιακη θεραπεια για σκληρυνση κατα πλακας
MX2021006945A (es) Anelosomas para suministrar modalidades terapéuticas de reemplazo de proteínas.
EA201891138A1 (ru) Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
AR108687A1 (es) Terapia génica para el tratamiento de hemofilia a
HK40038616A (en) Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer
HK40025006A (en) Viral vectors encoding recombinant fix with increased expression for gene therapy of hemophilia b
NZ756883A (en) Adeno-associated virus factor viii vectors